|
|
|
|
Coles and top food companies reject genetically engineered canola
Greenpeace launches True Food Guide for easy GE-free shopping Sydney, Australia Australias culinary icon Margaret Fulton today launched the 'Canola Edition' of the Greenpeace True Food Guide in Sydney.The guide, which aims to help...
|
|
|
Oil rises above USD 50 per barrel
giving up early gains, as worries over the global economy returned to the fore centring on Citigroup's ability to survive, but hopes OPEC might cut output again as early as this week helped buoy prices.US light crude for January delivery...
|
|
|
Cystic Fibrosis - Findings from E.M. Westerman and co-authors broaden understanding of cystic fibrosis
Medical Devices & Surgical Technology Week Welcome to NewsRx!Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week We're a pay-per-view site for premium content! If you'd like to...
|
|
|
NRE Holdings Buys Cancer Care Center Bldg. for $6.5M
National Real Estate Holdings Inc., of El Dorado Hills, CA, purchased the medical-office building at 9461 Huron St.in Thornton, CO, from 9461 Huron Street LLC for $6.5 million, or approximately $345 per square foot. The 18,825-square...
|
|
|
World's most powerful toddler named
Katie Holmes and daughter Suri watch the LA Galaxy vs.Chelsea FC soccer game July 22, 2007 at the Home Depot Center in Carson, California. (Toby Canham, ) Tom Cruise and Katie Holmes' daughter Suri has been named the World's Most...
|
|
|
Designer Michael Kors to Present Runway Fashions at 'Destination Fashion 2009' and Grammy Award-Winning Trio T
Honorary Co-Chairs Tommy Lee Jones and Dawn Jones Join Nick and Marc Buoniconti, Dr.Barth Green for Memorable Night; Honorees for 'Women of Substance and Style' AnnouncedMIAMI, Nov. 18 /PRNewswire/ -- Today at a kickoff celebration...
|
|
|
Designer Michael Kors to Present Runway Fashions at 'Destination Fashion 2009' and Grammy Award-Winning Trio T
Honorary Co-Chairs Tommy Lee Jones and Dawn Jones Join Nick and Marc Buoniconti, Dr.Barth Green for Memorable Night; Honorees for 'Women of Substance and Style' Announced MIAMI, Nov. 18 /PRNewswire/ -- Today at a kickoff celebration...
|
|
|
Designer Michael Kors to Present Runway Fashions at 'Destination Fashion 2009' and Grammy Award-Winning Trio T
Honorary Co-Chairs Tommy Lee Jones and Dawn Jones Join Nick and Marc Buoniconti, Dr.Barth Green for Memorable Night; Honorees for 'Women of Substance and Style' Announced MIAMI, Nov. 18 /PRNewswire/ -- Today at a kickoff celebration...
|
|
|
Novartis Sips Up Nektar
Novartis has strengthened its capabilities for developing medicines that can be delivered via the lungs through a definitive agreement to acquire the pulmonary drug delivery business unit of Nektar Therapeutics for USD 115 million in cash.
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
/PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational eFlow Nebulizer System to ...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
/PRNewswire via COMTEX/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational eFlow Nebulizer...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
ONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., Nov.10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational...
|
|
|
Novartis Sips Up Nektar, and Its Inhalable (ie, Exubera) Intellectual Property
Novartis has strengthened its capabilities for developing medicines that can be delivered via the lungs through a definitive agreement to acquire the pulmonary drug delivery business unit of Nektar Therapeutics for USD 115 million in cash.
|
|
|
Cancer-Battling Christina Applegate: 'Today Is All I've Got'
filed under: Out Sick, TV News PrintShare Text SizeAAA (Nov.5) Christina Applegate's recovery from breast cancer isn't easy. She's tired all the time, has had to rethink her lifestyle, yet still, the 'Samantha Who?' actress isn't afraid...
|
